Gill JH - Search Results

1

Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.

Gill JH, Rockley KL, De Santis C, Mohamed AK. Gill JH, et al. Pharmacol Ther. 2019 Oct;202:18-31. doi: 10.1016/j.pharmthera.2019.06.001. Epub 2019 Jun 5. Pharmacol Ther. 2019. PMID: 31173840 Review.

2

Chronic cardiovascular toxicity in the older oncology patient population.

Findlay SG, Gill JH, Plummer R, DeSantis C, Plummer C. Findlay SG, et al. Among authors: gill jh. J Geriatr Oncol. 2019 Sep;10(5):685-689. doi: 10.1016/j.jgo.2019.01.018. Epub 2019 Feb 5. J Geriatr Oncol. 2019. PMID: 30733001 Review.

3

Pyridylphosphinate metal complexes: synthesis, structural characterisation and biological activity.

Cross JM, Gallagher N, Gill JH, Jain M, McNeillis AW, Rockley KL, Tscherny FH, Wirszycz NJ, Yufit DS, Walton JW. Cross JM, et al. Among authors: gill jh. Dalton Trans. 2016 Aug 9;45(32):12807-13. doi: 10.1039/c6dt01264g. Dalton Trans. 2016. PMID: 27468432

4

Anticancer Ru^II and Rh^III Piano-Stool Complexes that are Histone Deacetylase Inhibitors.

Cross JM, Blower TR, Gallagher N, Gill JH, Rockley KL, Walton JW. Cross JM, et al. Among authors: gill jh. Chempluschem. 2016 Dec;81(12):1276-1280. doi: 10.1002/cplu.201600413. Epub 2016 Oct 12. Chempluschem. 2016. PMID: 31964062

5

Tumour endoproteases: the cutting edge of cancer drug delivery?

Atkinson JM, Siller CS, Gill JH. Atkinson JM, et al. Among authors: gill jh. Br J Pharmacol. 2008 Apr;153(7):1344-52. doi: 10.1038/sj.bjp.0707657. Epub 2008 Jan 21. Br J Pharmacol. 2008. PMID: 18204490 Free PMC article. Review.

6

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.

Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH. Atkinson JM, et al. Among authors: gill jh. Cancer Res. 2010 Sep 1;70(17):6902-12. doi: 10.1158/0008-5472.CAN-10-1440. Epub 2010 Jul 27. Cancer Res. 2010. PMID: 20663911 Free PMC article.

7

Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity.

Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, Patterson LH, Falconer RA. Gill JH, et al. Mol Pharm. 2014 Apr 7;11(4):1294-300. doi: 10.1021/mp400760b. Epub 2014 Mar 27. Mol Pharm. 2014. PMID: 24641451

8

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH. Sutherland M, et al. Among authors: gill jh. Mol Cancer Ther. 2013 Jan;12(1):27-37. doi: 10.1158/1535-7163.MCT-12-0405. Epub 2012 Oct 1. Mol Cancer Ther. 2013. PMID: 23033491

9

GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.

Seargent JM, Yates EA, Gill JH. Seargent JM, et al. Among authors: gill jh. Br J Pharmacol. 2004 Dec;143(8):933-7. doi: 10.1038/sj.bjp.0705973. Epub 2004 Nov 8. Br J Pharmacol. 2004. PMID: 15533890 Free PMC article.

10

Identification of Novel Benzoxa-[2,1,3]-diazole Substituted Amino Acid Hydrazides as Potential Anti-Tubercular Agents.

Brown AK, Aljohani AKB, Gill JH, Steel PG, Sellars JD. Brown AK, et al. Among authors: gill jh. Molecules. 2019 Feb 23;24(4):811. doi: 10.3390/molecules24040811. Molecules. 2019. PMID: 30813427 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page